Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Dose Rounding Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Dose Rounding for Systemic Therapy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Optum Cancer Guidance Program dose rounding for selected Medicare Part B systemic cancer drugs, including dose-rounding criteria, prior authorization handling, and provider requirements when rounded doses are accepted or declined.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Dose Rounding for Systemic Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through MBMNow.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    <10%Maximum dose reduction for recommended rounding
    ≥10%Weight change requiring a new authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Select cancer drugs
    Dose-rounding drug table

    When Dose Rounding Applies

    When dose rounding applies

    Dose rounding applies when all of the following conditions are met.

    Dose-rounding conditions

    • Eligible dose reduction: The dose can be rounded down to the nearest vial size by less than 10% of the NCCN-recommended dose per treatment.<10%
    • Fewer vials: The rounded dose results in the use of fewer vials per treatment and less waste.
    • No efficacy reduction: The rounding does not reduce treatment efficacy.

    Dose rounding is not applied when rounding down to the nearest vial size would not result in the use of fewer vials per treatment.

    Dose-Rounding Drug Table and Thresholds

    Covered HCPCS CodesHCPCSCovered
    J0893Decitabine(sun pharma)
    J0894Decitabine (Dacogen®)
    J9025Azacitidine (Vidaza®)
    J9033Bendamustine (Treanda®)
    J9035Bevacizumab (Avastin®)
    J9042Bortezomib (Velcade®) = Brentuximab (Adcetris®)
    J9043Bortezomib (Velcade®) = Cabazitaxel (Jevtana®)
    J9046Bortezomib (Velcade®) = Bortezomib(dr. reddy's)
    J9064Bortezomib (Velcade®) = Cabazitaxel
    J9047Bortezomib (Velcade®) = Carfilzomib (Kyprolis®)
    1–10 of 45
    1/5
    Dose reduction for rounding
    Dose reduction thresholdLess than 10%
    Reference doseNCCN-recommended dose per treatment
    Rounding directionRound down to the nearest vial size
    Weight change requiring new authorization
    Weight-change thresholdAt least 10%
    TimingDuring the course of therapy
    Required actionSubmit a new authorization so the total authorized dose is not exceeded

    Prior Authorization and Treatment Management

    Prior Authorization

    Submit Through MBMNow

    Submit the cancer treatment prior authorization through MBMNow. A provider or operations user may submit the request, after which Optum’s Cancer Guidance Program automatically evaluates whether dose rounding applies.

    Note

    Review and Accept the Rounded Dose

    MBMNow may offer a rounded dose when rounding down by less than 10% of the NCCN-recommended dose uses fewer vials and reduces waste. If the provider accepts the offered rounded dose, the request may be automatically approved; the authorization will reflect the total approved billable units for the treatment course and approved cycles. Acceptance is voluntary and is not required to receive cancer-treatment prior authorization.

    Unsupported block type: prior_auth

    Documentation Required

    Purpose of Dose Rounding

    The policy uses dose rounding for selected systemic cancer therapies to reduce drug waste, minimize healthcare worker exposure, support treatment accuracy and efficacy, and reduce the total cost of cancer care. Rounding is limited to cases where the dose can be reduced by less than 10% of the NCCN-recommended dose per treatment without reducing treatment efficacy and where fewer vials are used.

    Key Definitions

    Dose rounding
    Dose roundingRounding down the NCCN-recommended dose per treatment by less than 10%
    Rounding endpointThe nearest vial size
    Fewer vials requirementRounding must result in the use of fewer vials per treatment without reducing treatment efficacy
    Significant weight change
    Significant weight changeA member weight change of at least 10%
    Measurement periodDuring the course of therapy
    Authorization requirementA new authorization must be submitted to ensure the total authorized dose is not exceeded

    Initial Dose-Rounding Evaluation

    Initial dose-rounding evaluation

    For an initial prior authorization request, dose rounding is considered for selected cancer drugs when the calculated rounded dose meets the following conditions.

    Initial dose-rounding evaluation: The Cancer Guidance Program calculates the per-treatment dosage using the member's height and/or weight and the NCCN-recommended dosage for the regimen. A rounded dose may be recommended when rounding down by less than 10% results in fewer vials per treatment without reducing treatment efficacy.<10%

    Acceptance of the rounded dose is voluntary and is not required to receive prior authorization for cancer treatment.

    Continuation Therapy and Weight Change

    Continuation therapy and weight change

    During an approved treatment course, continuation requires reassessment when the member's weight changes significantly.

    Continuation authorization: If the member's weight changes by at least 10% during the course of therapy, a new authorization must be submitted to ensure the total authorized dose is not exceeded.≥10% weight change
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Dose Rounding for Systemic Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through MBMNow.
    SourceLink
    On This Page
    When Dose Rounding AppliesDose-Rounding Drug Table and ThresholdsPrior Authorization and Treatment ManagementPurpose of Dose RoundingKey DefinitionsInitial Dose-Rounding EvaluationContinuation Therapy and Weight Change

    Provide Dose Calculation Inputs

    MBMNow calculates the per-treatment dosage using the member’s height and/or weight together with the NCCN-recommended dosage for the applicable regimen.

    • These inputs are used to determine whether dose rounding applies and to calculate the treatment dose.
    Documentation Required

    Prepare for Custom Review

    If the offered rounded dose is not accepted, the request will require custom review. A Cancer Guidance Program Nurse may contact the provider for additional information.

    Denial Risk

    Declined Rounded Dose Requires Review

    Declining the rounded dose requires custom review and may require the provider to supply additional clinical information before the request is resolved.

    • Clinicians should use independent medical judgment in the context of the member’s individual clinical circumstances.
    Prior Authorization

    Manage Dose Changes During Therapy

    During the course of therapy, submit a new authorization after a member’s weight changes by at least 10% so the total authorized dose is not exceeded.

    • Care decisions remain between the provider and member.